419 related articles for article (PubMed ID: 34512654)
1. Scoring System Based on RNA Modification Writer-Related Genes to Predict Overall Survival and Therapeutic Response in Bladder Cancer.
Zhang P; Liu Z; Wang D; Li Y; Xing Y; Xiao Y
Front Immunol; 2021; 12():724541. PubMed ID: 34512654
[TBL] [Abstract][Full Text] [Related]
2. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
3. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
[TBL] [Abstract][Full Text] [Related]
4. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
[TBL] [Abstract][Full Text] [Related]
5. The construction and validation of an RNA binding protein-related prognostic model for bladder cancer.
Chen F; Wang Q; Zhou Y
BMC Cancer; 2021 Mar; 21(1):244. PubMed ID: 33685397
[TBL] [Abstract][Full Text] [Related]
6. Identification of immune-related LncRNA for predicting prognosis and immunotherapeutic response in bladder cancer.
Wu Y; Zhang L; He S; Guan B; He A; Yang K; Gong Y; Li X; Zhou L
Aging (Albany NY); 2020 Nov; 12(22):23306-23325. PubMed ID: 33221763
[TBL] [Abstract][Full Text] [Related]
7. Establishment of a novel risk score model by comprehensively analyzing the immunogen database of bladder cancer to indicate clinical significance and predict prognosis.
Liu L; Hu J; Wang Y; Sun T; Zhou X; Li X; Ma F
Aging (Albany NY); 2020 Jun; 12(12):11967-11989. PubMed ID: 32570217
[TBL] [Abstract][Full Text] [Related]
8. Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Signature Contributes to Predicting Prognosis and Tumor Microenvironment of Bladder Cancer.
Lu H; Wu J; Liang L; Wang X; Cai H
Front Immunol; 2022; 13():803355. PubMed ID: 35154117
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
[TBL] [Abstract][Full Text] [Related]
10. A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer.
Liu Z; Qi T; Li X; Yao Y; Othmane B; Chen J; Zu X; Ou Z; Hu J
Front Immunol; 2021; 12():791924. PubMed ID: 34975891
[TBL] [Abstract][Full Text] [Related]
11. Development of a prognostic index and screening of prognosis related genes based on an immunogenomic landscape analysis of bladder cancer.
Qu G; Liu Z; Yang G; Xu Y; Xiang M; Tang C
Aging (Albany NY); 2021 Apr; 13(8):12099-12112. PubMed ID: 33888644
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J
J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787
[TBL] [Abstract][Full Text] [Related]
13. A potential prognostic lncRNA signature for predicting survival in patients with bladder urothelial carcinoma.
Bao Z; Zhang W; Dong D
Oncotarget; 2017 Feb; 8(6):10485-10497. PubMed ID: 28060759
[TBL] [Abstract][Full Text] [Related]
14. Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer.
Chen X; Qin Z; Zhu X; Wang L; Li C; Wang H
Sci Rep; 2023 Dec; 13(1):21816. PubMed ID: 38071230
[TBL] [Abstract][Full Text] [Related]
15. An EMT-related gene signature for the prognosis of human bladder cancer.
Cao R; Yuan L; Ma B; Wang G; Qiu W; Tian Y
J Cell Mol Med; 2020 Jan; 24(1):605-617. PubMed ID: 31657881
[TBL] [Abstract][Full Text] [Related]
16. A Three Protein-Coding Gene Prognostic Model Predicts Overall Survival in Bladder Cancer Patients.
Ning XH; Qi YY; Wang FX; Li SC; Jia ZK; Yang JJ
Biomed Res Int; 2020; 2020():7272960. PubMed ID: 33150179
[TBL] [Abstract][Full Text] [Related]
17. Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer.
Chen H; Yao J; Bao R; Dong Y; Zhang T; Du Y; Wang G; Ni D; Xun Z; Niu X; Ye Y; Li HB
Mol Cancer; 2021 Feb; 20(1):29. PubMed ID: 33557837
[TBL] [Abstract][Full Text] [Related]
18. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465
[TBL] [Abstract][Full Text] [Related]
20. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
Front Immunol; 2021; 12():725223. PubMed ID: 34484235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
